Retrospective Cohort Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Feb 27, 2020; 12(2): 34-44
Published online Feb 27, 2020. doi: 10.4240/wjgs.v12.i2.34
Retrospective cohort study of statin therapy effect on resected colorectal liver metastases
Edward Alabraba, Hussain Ibrahim, Adina Olaru, Iain Cameron, Dhanny Gomez, Nottingham HPB Surgery Group
Edward Alabraba, Hussain Ibrahim, Adina Olaru, Iain Cameron, Dhanny Gomez, Department of Hepatobiliary Surgery and Pancreatic Surgery, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, United Kingdom
Dhanny Gomez, NIHR Nottingham Digestive Disease Biomedical Research Unit, University of Nottingham, Nottingham NG7 2UH, United Kingdom
Author contributions: Gomez D, Cameron I and Alabraba E designed the research; Ibrahim H, Olaru A and Alabraba E collected the data; Gomez D and Alabraba E analyzed the data; Alabraba E, Ibrahim H, Olaru A, Cameron I and Gomez D wrote the paper.
Institutional review board statement: Notiingham University Hospitals NHS Trust granted institutional board approval (project number 18-320c) was obtained and the project adhered to ethical guidelines.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous data that were obtained after each patient agreed and provided written consent to have treatment.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
STROBE statement: The authors have read and used the STROBE Statement as a guide in preparing and revising the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Dhanny Gomez, FRCS, Surgeon, Consultant Surgeon, Department of Hepatobiliary Surgery and Pancreatic Surgery, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, E Floor, West Block, Queen’s Medical Centre, Derby Road, Nottingham NG7 2UH, United Kingdom. dhanny.gomez@nuh.nhs.uk
Received: September 27, 2019
Peer-review started: September 27, 2019
First decision: October 24, 2019
Revised: November 24, 2019
Accepted: December 14, 2019
Article in press: December 14, 2019
Published online: February 27, 2020
Core Tip

Core tip: Colorectal liver metastases (CRLM) develop in 25%-30% of patients with colorectal cancer and disease prevalence has increased with expansion in the at-risk older age group. The need for chemoprevention to inhibit carcinogenesis is an attractive option that has shown promise in patients at high risk of developing CRLM. Observational studies have shown statins are promising chemopreventive agents but no data exist specifically for CRLM. Statins represent a well-established drug group whose pharmacodynamic properties are familiar to clinicians and if they demonstrate effectiveness as chemoprevention for CRLM, repurposing statins for this use will be more cost- and time- effective compared to developing new agents.